In addition, the missense TYK2 I684S, described as producing a catalytically impaired kinase [25] and associated to protection against autoimmune diseases [48], was detected in eleven patients (17.74%) of our sequenced cohort, matching the frequency reported for AML patients [21], which is threefold the frequency found in T-ALL samples [32]. This evidence concerns the gene TYK2 and acute myeloid leukemia.